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  The purpose of our study was to create a novel rat aorta 
stent implantation model. Stainless steel bare metal stents 
(BMS) or paclitaxel-eluting stents (PES) were implanted 
in male Sprague-Dawley rats (BW 400 ±  20 g). Two and 
four weeks after stent implantation, the aorta were collected, 
fixed with 2% glutaraldehyde, and cut into two segments. 
One segment was used for scanning electron microscopy 
analysis  to  evaluate  re-endothelialization,  and  the  other 
segment was used to calculate the neointimal area. At 2 
weeks  after  stenting,  the  appearance  of  neointimal 
hyperplasia was less in the PES group than in the BMS 
group. At 4 weeks after stenting, no significant difference 
in  neointimal  hyperplasia  was  observed  between  two 
groups. On the other hand, the PES group showed more 
thrombus formation and less re-endothelialization compared 
to the BMS group. This study demonstrated the ability of 
a novel rat model of aorta stenting via a common carotid 
artery to measure the efficacy and safety of commercially 
available drug-eluting stents.
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Introduction 
Atherosclerotic vascular disease and the resulting 
sequelae remain the leading cause of death in developed 
countries worldwide. Stenting is the most frequently 
performed percutaneous intervention for the treatment of 
coronary artery disease. However, re-occlusion due to 
stent thrombosis in the early period and in-stent restenosis 
in the later period after stent deployment are principal 
drawbacks of coronary stenting. To attenuate in-stent 
restenosis, many researchers have studied the effects of 
new polymers, metals, stent architecture, and drugs on the 
inhibition of neointimal hyperplasia.
The animal models most commonly used to assess 
vascular responses to stent implantation are the porcine 
coronary artery model [19,27] and the rabbit iliac artery 
model [2,13]. The porcine coronary artery stenting model 
[11,24] is suitable for research because the porcine heart is 
similar to the human heart in terms of pathologic and 
physiologic vascular responses. However, the rapid growing 
pigs results in a high cost of breeding. The rabbit iliac 
artery stenting model [7,13] has the advantage of a low cost 
but the pathologic and physiologic responses of rabbits 
differ from those in humans. In addition, it is widely 
recognized that arterial repair after stent placement in 
animals occurs more rapidly than in humans although the 
sequence of biological events associated with healing are 
remarkably similar [28]. However, Finn et al. [9] reported 
a significant difference in the rate of healing between the 
porcine model and the rabbit model. After placement of a 
bare metal stent (BMS), the porcine model showed 
completed endothelialization by 14 days whereas it took 21 
days to complete this process in the rabbit model. 
Previous studies in the porcine or rabbit model used both 
drug-eluting stents and BMS [2,4]. In this study, to 
demonstrate the validity of our novel rat model in 
comparison with these previous animal models, we 
implanted BMS and paclitaxel-eluting stents (PES) and 
assessed stent re-endothelialization, neointimal hyperplasia, 
and thrombus formation 2 and 4 weeks after stent 
implantation. 
Materials and Methods 
Animal care, stent deployment, and aortogram
All animal protocols were approved by the Chonnam 
National University Animal Care and Use Committee 
(CNU IACUC-H-2009-18). Male Sprague-Dawley rats 144    Jin Sook Kwon et al.
were purchased from Samtako (Korea). All rats (b.w. 400 
± 20 g) were fed a normal pelleted diet and were given 
water ad libitum. Starting 1 week before stent implantation 
and continuing throughout the study period, the rats’ 
drinking water contained aspirin (3.25 mg/kg; Bayer Vital, 
Germany) and clopidogrel (0.75 mg/kg, Plavix; Sanofi- 
Aventis, USA).
In the baseline study, a total of 14 rats underwent an 
aortogram and surgery. We measured the aorta size of 10 
rats by angiogram before stent implantation. To select the 
optimal stent size (diameter and length), balloon pressure, 
and stent-to-artery ratio, the aorta size of the rats that 
underwent stent implantation was measured by angiogram. 
A balloon pressure of 9 atm resulted in a stent-to-artery 
ratio into 1：1.2. A BMS (n = 6, Liberté 3.5 × 20 mm; 
Boston Scientific, USA) or a PES (n = 6, Taxus Liberté 3.5 
× 20 mm; Boston Scientific, USA) was deployed at 9 atm 
in the rats. 
For stent implantation, the rats were anesthetized with an 
intraperitoneal injection of ketamine (50 mg/kg; Bayer 
Animal Health, Korea) and xylazine (6.7 mg/kg; Bayer 
Animal Health, Korea), and the left common carotid artery 
was surgically exposed. The proximal portion of the left 
common carotid artery was ligated with 5-0 silk thread. 
The distal portion was then occluded by a vessel clamp to 
block blood flow and a carotid cut down was performed at 
the mid portion. Under fluoroscopic guidance [7,18], the 
stent catheter was advanced to the thoracic aorta via the left 
common carotid arteriotomy. A 0.36 mm percutaneous 
transluminal coronary angioplasty (PTCA) guide wire was 
advanced into the thoracic aorta. A BMS or PES with a 
balloon-to-artery ratio ranging from 1：1.2 to 1：1.3 was 
placed at the desired location in the thoracic aorta and 
inflated to 9 atm of balloon pressure. After stent deployment, 
the animals were allowed to recover in their normal 
housing at the animal care facility. The animals were 
monitored daily until the subsequent experimental 
procedures and euthanasia 2 or 4 weeks after stent 
placement.
Aortography was performed 2 or 4 weeks after stent 
deployment (Fig. 1A) using a contrast agent (Visipaque; 
Amersham Health, Ireland). An angiography catheter (18 
G radiology needles; BD, USA) was introduced through 
the right common carotid artery and advanced to the 
thoracic aorta to deliver the contrast agent. Aorta size was 
calculated by quantitative angiography before stent 
implantation. Stent size and balloon pressure were also 
determined. The stent-to-artery ratio was calculated by 
dividing the post-implant aorta diameter by the pre- 
implant aorta diameter.
Tissue preparation and histomorphometric analysis 
At 2 and 4 weeks after stent implantation, the rats were 
anesthetized with an intraperitoneal injection of ketamine 
and xylazine. After the final aortogram, the aorta was 
flushed gently with a 0.9% saline solution and perfusion 
fixation was performed with 2.5% glutaraldehyde. The 
stented aorta was harvested with at least 1 cm of the 
proximal and distal margin. After an additional 24 h of 
immersion fixation with 2.5% glutaraldehyde, the stented 
aorta was cut into two segments.
One segment of the stented aorta was used for scanning 
electron microscopy (SEM) analysis. SEM analysis was 
conducted by following standard procedures. In brief, the 
stented aorta was fixed with 2.5% glutaraldehyde in 0.1 M 
cacodylate buffer (Sigma Aldrich, USA) for 2 h and then 
OsO4 for 90 min, followed by dehydration through a series 
of alcohols. The samples then underwent critical point 
drying before being coated with evaporated gold and 
observed under an S-3500N scanning electron microscope 
(Hitachi, Japan). The re-endothelialization ratio was 
calculated by using NIS-Elements (version 3.00 SP7; 
Nikon, Japan). 
The other segment of the stented aorta was placed in 10% 
formalin for an additional 24 h. Cross-sections were 
prepared from the segment by embedding the tissue in 
acrylic plastic and cutting sections 75 μm-thick. All 
sections were stained with hematoxylin and eosin. 
Histomorphometric analysis was carried out using Nis- 
Elements. The neointimal area was calculated as the media 
area minus the inner luminal area (neointimal area = media 
area − inner luminal area). These areas were determined 
in each section, averaged, and expressed as the absolute 
area in mm
2. Additionally, the uncovered strut ratio was 
determined by microscopic observation and calculated as 
exposed strut number / total strut number. The focal 
thrombus ratio was calculated as thrombus-containing 
strut number / total strut number as found by microscopic 
observation. These were averaged over all stained sections. 
At SEM analysis, the re-endothelization percentage (%) 
was calculated as the strut area minus the uncovered area 
divided by the strut area (re-endothelization percentage 
(%) = strut area − uncovered area / strut area) (Fig. 4Ab).
Statistical analysis
Measurements for each stented aorta (total sections from 
the mid to distal portion) were averaged to produce a mean 
value per stent. Tests for statistical significance were 
two-tailed, and significance was established by a p-value 
＜ 0.05 (v 16.0; SPSS, USA). Unless otherwise noted, data 
are represented as the mean ± SD.
Results
Establishment of the rat aorta stent model
The total procedure time for stent implantation in the rat 
aorta was approximately 15 to 20 min. Four rats died 
during surgery due to bleeding from the carotid artery at the Comparison of bare metal stent and paclitaxel-eluting stent using a novel rat aorta stent model    145
Fig. 1. Establishment of a novel aorta stent implantation 
procedure in rats. Representative illustrations and fluoroscopic 
angiographs of the implantation of a bare metal stent or 
paclitaxel-eluting stent in the thoracic aorta. (A) Operation 
procedure. (B) and (C) Operation procedure involved a guide 
wire that was advanced in the thoracic aorta after excision of the
left common carotid artery and a stent inserted into the thoracic 
aorta. (D) Follow-up thoracic angiography was performed with a 
catheter in the right common carotid artery. 
Fig. 2. (A) 2 weeks (wk) and (B) 4 wk after implantation of the bare metal stent (BMS) or paclitaxel-eluting stent (PES). (C) Thrombus
in the outer and inner area of the neointima at 4 wk. Scale bars = Aa and b, Ba and b: 1 mm; Ac and d, Bc and d, C: 50 μm. H&E stain.
site of incision. All stented aorta (n = 12) in the surviving 
rats were patent. The operation procedure is illustrated in 
Fig. 1A. The left common carotid artery was exposed and 
PTCA guide wire was inserted into the carotid artery. The 
stent was then inserted into the thoracic aorta via the guide 
wire (Figs. 1B and C). At 2 or 4 weeks after stent 
implantation, angiography was performed with an 18 G IV 
catheter in the right carotid artery (Fig. 1D). Quantitative 
angiograms at each time point (2 or 4 weeks after stenting) 
showed that the stents were implanted with similar stent- 
to-artery ratios.
Histomorphometric analysis
The neointimal area was larger in the BMS group (0.262 
± 0.010 mm
2) than in the PES group (0.170 ± 0.014 mm
2) 
at 2 weeks following stent placement (p ＜ 0.05) (Figs. 2A 
and 3A). However, no significant difference in the 
neointimal area was observed between the two groups 
[BMS group: 0.567 ± 0.055 mm
2 vs. PES group: 0.618 ± 
0.089 mm
2 (p ＞ 0.05)] at 4 weeks (Figs. 2A and 3C). The 
uncovered strut ratio was 38.3 ± 16.5% in the BMS group 
and 84.2 ± 1.1% in the PES group at 2 weeks, and 8.3 ± 
4.0% in the BMS group and 45.0 ± 7.1% in the PES group 
at 4 weeks (Fig. 2B). The focal thrombus ratio was 0.0 ± 146    Jin Sook Kwon et al.
Fig. 3. Histomorphometric results of BMS or PES implantation. (A) Neointimal area. (B) Representation of neointimal area, media area
(green line) and inner luminal area (square line). (C) Uncovered strut ratio. (D) Focal thrombus ratio. BMS 2 wk vs. PES 2 wk (*p ＜
0.05). BMS 4 wk vs. PES 4 wk (**p ＜ 0.05), BMS 2 wk vs. BMS 4 wk (
#p ＜ 0.05), PES 2 wk vs. PES 4 wk (
##p ＜ 0.05).
0.0% in the BMS group and 29.4 ± 8.9% in the PES group 
at 2 weeks and 5.0 ± 7.1% in the BMS group and 51.3 ± 
8.3% in the PES group at 4 weeks. In addition, thrombi 
were detected only in the neointimal area (Figs. 2C and 
3D).
SEM evaluation of re-endothelialization 
At SEM analysis, the portion of the stent struts that 
remained uncovered was less in the BMS group than in the 
PES group at 2 weeks after stent implantation. Stent 
detachment was observed in the PES group (Fig. 4B). As 
seen in Figs. 4C and D, the portion of the stent struts that 
was covered increased in both groups at 4 weeks. The BMS 
struts were mostly covered (93 ± 4%), but the PES struts 
were not sufficiently covered (53 ± 18%) (p ＜ 0.05). The 
strut was covered by endothelial cells in the BMS group 
(Fig. 4E, green arrows). In the PES group, non-endothelial 
cells such as inflammatory cells and platelets were 
detected on the stent surface (Fig. 4E, yellow arrows).
Discussion
In this study, we developed a novel aorta stent model in 
rats that is similar to percutaneous implantation of a 
coronary stent in human, and compared the effects of BMS 
with those of PES. Our aorta stent model in rats has several 
advantages. First, the stent site was not exposed to the 
external environment. Therefore, it was protected from 
complications caused by inflammation and tissue adhesion. 
In addition, stent implantation was performed using human 
stent implantation devices. Rats are ideal for biochemical 
and biological analyses compared to pig models because 
they can be easily studied with various commercially 
available antibody and ELISA kits. In addition, rats have 
various disease models such as transgenic, obese, 
atherosclerotic, diabetic, and hypertensive strains Moreover, 
knockout rat strains are becoming increasingly available.
Langeveld et al. [18], Indolfi et al. [12], and Finn et al. [7] 
used an open abdominal aorta stent rat model or deployed 
a small-caliber stent into the carotid artery in the rat. The 
open abdominal aorta model is very useful, but exposure of Comparison of bare metal stent and paclitaxel-eluting stent using a novel rat aorta stent model    147
Fig. 4. Scanning electron microscopy photographs of BMS and 
PES in rat aorta. (A) Representation of strut area (blue) and 
uncovered area (red). (B) BMS and PES at 2 wk and (C) at 4 wk.
(D) The covered stent ratio at 4 wk after stent implantation. (E) 
High magnification. Endothelial cells (green arrow), inflammatory
cells (yellow arrow), and stent strut (red arrow). *p ＜ 0.05. Ba 
and Ea: BMS 2 wk, Bb and Eb: PES 2 wk, Ca and Ec: BMS 4 wk, 
Cb and Ed: PES 4 wk. Scale bars = Aa: 500 μm, B and C: 1 mm, 
Ea and b: 100 μm, Ec and d: 50 μm. 
the abdominal cavity and abdominal aorta to the external 
environment may cause reactions such as inflammation 
and adhesion. Additionally, the rat carotid artery cannot be 
accessed by commercially manufactured coronary stents. 
Our model did not require microsurgical equipment or 
special skills. Furthermore, we used commercially available 
BMS and PES in the rat thoracic aorta.
In previous report, PES has been shown to reduce the rate 
of restenosis and late lumen loss compared to BMS, 
resulting in a significant reduction in the need for target 
vessel revascularization [23]. However, an increased risk 
of late stent thrombosis (defined as thrombosis ≥ 30 days 
after stent deployment) has been identified as a major 
safety concern [1,3,6,14-17,21,22,25,26]. This concept is 
based on clinical autopsy and intracoronary angioscopic 
studies [5,10,16]. In the present study, the aorta stent model 
in SD rats showed vascular reaction patterns of re- 
endothelialization, neointimal induction, and thrombus 
formation similar to those in a swine model [8-10]. 
However, the induction of neointimal hyperplasia was 
weaker in our rat model than in the swine model. 
By SEM analysis, the percentage of the stent area covered 
in the rats was found to be over 90% in the BMS group and 
about 50% in the PES group at 4 weeks after stent 
implantation. Experiments in a porcine coronary stent 
model have suggested that re-endothelialization was 
complete at 28 days after stent placement [8]. However, in 
another study, re-endothelialization was clearly delayed 
when a PES was implanted in a rabbit iliac artery [4].
The histological analysis showed that the neointimal area 
was increased at 4 weeks compared to 2 weeks. The extent 
of neointimal hyperplasia was less in the PES group than in 
the BMS group at 2 weeks. In the PES group, decreased 
neointimal hyperplasia was related to the paclitaxel 
coating of the stent strut surface. No difference in neointimal 
hyperplasia was observed 4 weeks after stenting between 
the BMS and PES group. This phenomenon might be 
called “late catch-up.” In the BMS group, neointimal 
formation gradually increased between 2 and 4 weeks after 
stent implantation. In the PES group, however, reduced 
neointimal formation observed until 2 weeks suddenly 
increased between 2 and 4 weeks after stent implantation.
Thrombus formation could be a possible factor in late 
catch-up. In our study, thrombi were detected in the PES 
group in the outer area of the neointima at 2 weeks and in 
the inner area of the neointima at 4 weeks. From our 
experiments, we can hypothesize that the PES inhibited 
neointimal formation during the early phase, but caused 
thrombus formation and restenosis during the later phase.
In conclusion, we have demonstrated the creation of a 
novel model of aorta stenting via the common carotid 
artery in rats. Our model showed similar vascular 
responses after implantation of BMS and PES in normal rat 
aorta compared to pig and rabbit models. This model had 
the disadvantage of weaker neointimal hyerplasia 
compared to the pig coronary artery stent model [20], but 
had the advantages of enabling the detection of thrombi, re- 
endothelialization analysis, histomorphometric analysis, 
easy handling, and low cost. In addition, our model will 
allow relative long-term follow-up and research on aged 
animals because of the short life-span. 
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